Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review
Seyedeh Alia Moosavian, Thozhukat Sathyapalan, Tannaz Jamialahmadi, et al.
Bioinorganic Chemistry and Applications (2021) Vol. 2021, pp. 1-13
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review
Narjes Nasiri‐Ansari, Θεόδωρος Ανδρουτσάκος, Christina‐Maria Flessa, et al.
Cells (2022) Vol. 11, Iss. 16, pp. 2511-2511
Open Access | Times Cited: 76
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 31
Management of metabolic-associated fatty liver disease: The diabetology perspective
Mohammad Sadiq Jeeyavudeen, Shahanas K A Khan, Sherouk Fouda, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 1, pp. 126-143
Open Access | Times Cited: 34
Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery
Inês Domingues, Isabelle Leclercq, Ana Beloqui
Journal of Controlled Release (2023) Vol. 363, pp. 415-434
Closed Access | Times Cited: 28
RGD-engineered nanoparticles as an innovative drug delivery system in cancer therapy
Mehdi Sanati, Amir R. Afshari, Samaneh Aminyavari, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 84, pp. 104562-104562
Closed Access | Times Cited: 26
Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives
Janitha M. Unagolla, Subarna Das, Riley Flanagan, et al.
International Journal of Pharmaceutics (2024) Vol. 660, pp. 124381-124381
Closed Access | Times Cited: 6
Nanodrug Delivery Systems for Metabolic Chronic Liver Diseases: Advances and Perspectives
Foteini Athanasopoulou, Michail Manolakakis, Santiago Vernia, et al.
Nanomedicine (2023) Vol. 18, Iss. 1, pp. 67-84
Open Access | Times Cited: 15
Mesenchymal stem cell-derived exosomes for management of prostate cancer: An updated view
Fahimeh Lavi Arab, Akram Hoseinzadeh, Fatemeh Hafezi, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112171-112171
Closed Access | Times Cited: 5
Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
Ali Mahmoudi, Seyed Adel Moallem, Thomas P. Johnston, et al.
PPAR Research (2022) Vol. 2022, pp. 1-12
Open Access | Times Cited: 22
Recent Updates on Applications of Lipid-Based Nanoparticles for Site- Specific Drug Delivery
Shivanshu Agrawal, Anuj Garg, Vikas Varshney
Pharmaceutical Nanotechnology (2022) Vol. 10, Iss. 1, pp. 24-41
Closed Access | Times Cited: 21
Aptamers against cancer drug resistance: Small fighters switching tactics in the face of defeat
Mehdi Sanati, Amir R. Afshari, Seyed Sajad Ahmadi, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2023) Vol. 1869, Iss. 6, pp. 166720-166720
Closed Access | Times Cited: 12
Oral nanomedicine biointeractions in the gastrointestinal tract in health and disease
Cheng Chen, Ana Beloqui, Yining Xu
Advanced Drug Delivery Reviews (2023) Vol. 203, pp. 115117-115117
Closed Access | Times Cited: 12
Tanshinone IIA Against Cerebral Ischemic Stroke and Ischemia- Reperfusion Injury: A Review of the Current Documents
Reza Arefnezhad, Alireza Nejabat, Fatemeh Behjati, et al.
Mini-Reviews in Medicinal Chemistry (2024) Vol. 24, Iss. 18, pp. 1701-1709
Closed Access | Times Cited: 4
Exploration of capsaicin-encapsulated lignin nanoparticles for alleviating non-alcoholic fatty liver disease: In-vitro study
Jhalak Mehta, Pankaj Kumar, Sandip V. Pawar
International Journal of Biological Macromolecules (2025) Vol. 303, pp. 140616-140616
Closed Access
Advances in Nanotechnology for the Diagnosis and Management of Metabolic Dysfunction-associated Steatotic Liver Disease
Fenfen Li, Ruyan Yuan, Jiamin Zhang, et al.
Asian Journal of Pharmaceutical Sciences (2025), pp. 101025-101025
Open Access
Nanotherapeutics in metabolic diseases–Associated infections
V. P. Jaiswal, Shradha Bisht, Swati Prakash, et al.
Elsevier eBooks (2025), pp. 617-648
Closed Access
Cell and gene therapeutic approaches in non-alcoholic fatty liver disease
Mohadeseh Poudineh, Fatemeh Mohammadyari, Negin Parsamanesh, et al.
Gene (2025), pp. 149466-149466
Closed Access
State-of-the-Art Review on Liposomes as Versatile Cancer Vaccine Delivery Systems
Abulfazl Vatankhah, Fatemeh Oroojalian, Sepehr Hoseinzadeh Moghaddam, et al.
Journal of Drug Delivery Science and Technology (2025), pp. 106975-106975
Closed Access
The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
Amir Abbas Momtazi‐Borojeni, Maciej Banach, Massimiliano Ruscica, et al.
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 10, pp. 1199-1208
Closed Access | Times Cited: 18
Fabrication and investigation of a pentamerous composite based on calix[4]arene functionalized graphene oxide grafted with silk fibroin, cobalt ferrite, and alginate
Ehsan Bahojb Noruzi, Behrouz Shaabani, Reza Eivazzadeh‐Keihan, et al.
International Journal of Biological Macromolecules (2024) Vol. 259, pp. 129385-129385
Closed Access | Times Cited: 3
Recent advances of nanotechnology in the treatment and diagnosis of polycystic ovary syndrome
Mohammad Javad Javid-Naderi, Ali Mahmoudi, Prashant Kesharwani, et al.
Journal of Drug Delivery Science and Technology (2022) Vol. 79, pp. 104014-104014
Closed Access | Times Cited: 14
Atherosclerosis and Non-Alcoholic Fatty Liver Disease
Şevket Balta
Angiology (2022) Vol. 73, Iss. 8, pp. 701-711
Closed Access | Times Cited: 12
Antifibrotic activity of carbon quantum dots in a human in vitro model of non-alcoholic steatohepatitis using hepatic stellate cells
David A. García-Topete, Laura A. Álvarez-Lee, Gabriela I. Carballo-López, et al.
Biomaterials Science (2024) Vol. 12, Iss. 5, pp. 1307-1319
Closed Access | Times Cited: 2
Oligochitosan-based nanovesicles for nonalcoholic fatty liver disease treatment via the FXR/miR-34a/SIRT1 regulatory loop
Mengjie Kong, Peng Yan, Liyan Qiu
Acta Biomaterialia (2023) Vol. 164, pp. 435-446
Closed Access | Times Cited: 6
The Ethnopharmacological Properties of Green-Engineered Metallic Nanoparticles against Metabolic Disorders
Neha Rana, Sandeep Kumar Singh, A. Najitha Banu, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1022-1022
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top